ADMA Biologics (ADMA) vs Mirum Pharmaceuticals (MIRM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Mirum Pharmaceuticals (MIRM) has outperformed ADMA Biologics (ADMA) over the past year, gaining 16.5% versus a loss of 29.7%. Over five years, ADMA leads with a +841.8% price change compared with +402.4% for MIRM. Mirum Pharmaceuticals is the larger company by market cap ($5.58 billion vs $2.32 billion), about 2.4 times the size.
ADMA Biologics converts more of its revenue into profit, with a net margin of 28.8% versus -4.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADMA | MIRM |
|---|---|---|
| Share price | $10.36 | $86.01 |
| Market cap | $2.32B | $5.58B |
| 1-day change | +0.29% | +5.73% |
| YTD return | -43.20% | +8.89% |
| 1-year return | -29.72% | +16.51% |
| 5-year return | +841.82% | +402.39% |
| P/E ratio (TTM) | 14.80 | — |
| Forward P/E | 10.98 | — |
| EPS (TTM) | $0.70 | $-14.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $510.17M | $521.31M |
| Revenue growth (YoY) | +19.63% | +54.74% |
| Net income (latest FY) | $146.93M | $-23.36M |
| Gross margin | 57.39% | — |
| Operating margin | 37.53% | -4.25% |
| Net margin | 28.80% | -4.48% |
| 52-week high | $20.46 | $130.00 |
| 52-week low | $7.21 | $63.23 |
| Distance from 52-week high | -49.36% | -33.84% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +64.09% | +69.50% |
| Average volume | 2.66M | 695.76K |
| Shares outstanding | 223.98M | 64.93M |
| Employees | 640 | 433 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Mirum Pharmaceuticals is about 2.4 times larger than ADMA Biologics by market value ($5.58B vs $2.32B).
- MIRM has outperformed ADMA by 46.2 percentage points over the past year.
- ADMA Biologics is more profitable, keeping 28.8 cents of every revenue dollar as net income versus -4.5 cents for Mirum Pharmaceuticals.
- Mirum Pharmaceuticals grew revenue faster in its latest fiscal year (+54.74% vs +19.63%).
About ADMA Biologics
ADMA stock →ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 640 employees
About Mirum Pharmaceuticals
MIRM stock →Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 433 employees
ADMA vs MIRM FAQ
Which is bigger, ADMA Biologics or Mirum Pharmaceuticals?
Mirum Pharmaceuticals (MIRM) is larger, with a market capitalization of $5.58B compared with $2.32B for ADMA Biologics (ADMA).
Which stock has performed better over the past year, ADMA or MIRM?
MIRM returned +16.51% over the past 12 months, compared with -29.72% for ADMA (price return, excluding dividends). Past performance does not predict future results.
Are ADMA Biologics and Mirum Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for ADMA Biologics and Biotechnology: Pharmaceutical Preparations for Mirum Pharmaceuticals.